Mirion Technologies, Inc. (MIR): Results of Operations and Financial Condition
Mirion Technologies, Inc. (MIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026-07x28exhibit991.htm EX-99.1 Document Exhibit 99.1 News Release Mirion Announces Second Quarter 2026 Financial Results • Revenues for the second quarter increased 19.7% to $266.8 million, compared to $222.9 million in the same period in 2025. • GAAP net income was
How this was made
The 30-second read
Why it matters
The key tradable elements are the Q2 operating/cash metrics (adjusted EBITDA, adjusted free cash flow) and the reaffirmed 2026 guidance ranges, which together update the market’s earnings and cash-flow expectations.
Market read
Investors get a fresh quarterly datapoint set plus explicit 2026 guidance ranges, which can drive near-term re-rating and positioning ahead of the scheduled earnings call.
What to watch
The release notes Medical segment end-market composition adjustments; traders may want to watch whether that mix change affects margin sustainability or order quality into 2H 2026.
Background
This is an SEC 8-K with Exhibit 99.1 covering Mirion’s Q2 2026 results and full-year 2026 guidance reaffirmation.
Ticker impact
Mirion reported Q2 2026 revenue up 19.7% to $266.8M, with adjusted EBITDA up 27.5% to $65.3M, and reaffirmed full-year 2026 guidance.
Likely modest positive bias for the next session as traders digest the beat on adjusted EBITDA and the reaffirmed 2026 outlook.
The filing provides concrete quarterly datapoints (revenue, GAAP/adjusted EPS, adjusted EBITDA, orders) plus explicit guidance ranges that are reaffirmed, which typically drives earnings-model updates even without a guidance raise.
Market effects
Reinforces demand momentum in radiation detection and nuclear-related monitoring, potentially supporting sentiment for defense and nuclear-adjacent instrumentation peers.
No specific regional shock; commentary emphasizes North America nuclear power opportunities and international growth ambitions.
Guidance includes foreign exchange and acquisition tailwinds, so FX moves could matter for reported results versus organic growth.
Counterpoint
Organic revenue growth is only guided at 5% to 7%, so the stock may be sensitive if investors expected stronger underlying demand beyond acquisition and FX tailwinds.
Key entities
- companyMirion Technologies, Inc.
NYSE-listed radiation detection and monitoring solutions provider reporting Q2 2026 results and reaffirming 2026 guidance.
- corporate_actionsCertrec and Paragon acquisitions
Acquisitions referenced as augmenting order growth and nuclear power opportunity capture.
